Immunotherapy of genital warts with inosine pranobex and conventional treatment: double blind placebo controlled study.

AUTOR(ES)

Davidson-Parker, J

RESUMO

In a multicentre, prospective, randomised, placebo controlled study of 55 patients with histories of genital warts for at least one year, a four week course of inosine pranobex 3 g a day improved the clinical response to conventional treatment (primarily podophyllin or trichloroacetic (now called trichlorethanoic) acid). Although more patients given inosine pranobex improved than those given placebo, the difference in general response between the two groups was not significant. When other variables (numbers of warts and extent of lesions) were considered, however, the patients given inosine pranobex fared significantly better. These results suggest that inosine pranobex may be worth considering as adjunct to treatment of patients with refractory genital warts.

Documentos Relacionados

• Immunotherapy of genital warts with inosine pranobex (Imunovir): preliminary study.
• Randomised, double blind, placebo controlled trial of inosine pranobex in rheumatoid arthritis.
• Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study.
• Treatment of nongonococcal urethritis with trimethoprim-sulphadiazine and with placebo. A double-blind partner-controlled study.
• Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study.